A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

NCT01040728 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

122

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: Olodaterol (BI1744) Low
DRUG: Olodaterol (BI1744) High
DRUG: Tiotropium 18 mcg
DRUG: Placebo (for Olodaterol (BI1744)l)
DRUG: Placebo (for Tiotropium)

Sponsor

Boehringer Ingelheim